lingcong KONG | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

lingcong KONG | Drug Discovery and Development | Best Researcher Award

Prof. lingcong KONG at Jilin Agriculture University, China.

Prof. Lingcong Kong is a dedicated veterinary scientist with a Ph.D. in Preventive Veterinary Medicine from Jilin Agricultural University 🎓. He teaches courses like Veterinary Pharmacology and Animal Toxicology 🐄 and actively mentors students in national competitions 🏆. His research focuses on antimicrobial resistance, drug resistance mechanisms, and the development of resistance inhibitors in animal pathogens 🧫🦠. He has led numerous national and provincial projects, holds multiple patents for veterinary vaccines 💉, and has published extensively in high-impact journals 📚. His work significantly enhances diagnostic tools and contributes to sustainable animal healthcare.

Publication Profile 

Scopus

Education

Prof. Lingcong Kong began his academic journey at the Inner Mongolia University for Nationalities, where he earned his Bachelor of Veterinary Medicine from September 2006 to July 2010 🐾. He then pursued advanced studies at Jilin Agricultural University, completing a Master’s degree in Basic Veterinary Medicine between 2010 and 2013 🧪. Driven by a deep passion for animal health, he continued at the same institution to earn his Ph.D. in Preventive Veterinary Medicine from September 2013 to July 2016 🔬. His education laid a strong foundation for his impactful contributions to veterinary science and research.

Experience

Prof. Lingcong Kong is a dedicated educator who teaches undergraduate courses such as “Veterinary Pharmacology”, “Veterinary Pharmacology Experiment”, and “Animal Toxicology” 🐾. At the graduate level, he lectures on “Veterinary Drug Research and Creation”, “Advanced Pharmacology”, and “Veterinary Pharmacology and Toxicology” 💊. He actively mentors students in scientific competitions, leading them to prestigious honors like the 2022 Internet+ National Award (2nd Prize) 🏅, Provincial Award (1st Prize) 🥇, and innovation contests. His guidance also earned him the Outstanding Paper Award 📝 and the Dazenong Innovation Guidance Award in 2018 🎖️, highlighting his commitment to academic excellence and innovation.

Awards

Prof. Lingcong Kong has pioneered breakthroughs in detecting and combating drug-resistant animal pathogens 🐄🧫. His innovations include PCR-ELISA rapid detection, immunomagnetic bead enrichment, and high-throughput methods for resistance gene testing 🧪. He established a pathogenic bacteria resource library 📚 and developed functional probiotics to prevent animal diarrhea 💊. By identifying 8 key resistance inhibitor targets and 6 promising lead compounds, his work has revolutionized lab diagnostics, minimized economic losses in livestock, and enhanced ecological health 🌱💼. His efforts significantly advance animal healthcare and veterinary pharmacology across Jilin Province and beyond.

Research Focus 

Prof. Lingcong Kong focuses on veterinary pharmacology, particularly targeting antimicrobial resistance and infectious diseases in animals 🐄🦠. His cutting-edge research includes discovering novel natural inhibitors like coniferaldehyde and protocatechuic aldehyde to combat Staphylococcus aureus 🧪🔬. He also explores gene transfer mechanisms, antibiotic degradation pathways, and repurposing small molecules to inhibit bacterial enzymes like KPC-2 💊. By studying agents such as C15-bacillomycin D and antibacterial proteins from Bacillus velezensis, he contributes significantly to combatting multidrug-resistant pathogens in animal and environmental health.

Publication Top Notes

  • Discovery of coniferaldehyde as an inhibitor of caseinolytic protease to combat Staphylococcus aureus infections
  • Anti-infective therapy of inhibiting Staphylococcus aureus ClpP by protocatechuic aldehyde
  • Acidifiers promoted antibiotic resistance gene transfer via plasmid conjugation
  • Efficient degradation of tylosin by Kurthia gibsonii TYL-A1: performance, pathway, and genomics study
  • Repurposing tavaborole to combat resistant bacterial infections through competitive inhibition of KPC-2 and metabolic disruption
  • A Novel Protein Demonstrating Antibacterial Activity Against Multidrug-Resistant Escherichia coli Purified from Bacillus velezensis CB6
  • C15-bacillomycin D produced by Bacillus amyloliquefaciens 4-9-2 suppress Fusarium graminearum infection and mycotoxin biosynthesis

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Dr. Natalia Marina CARDILLO, USDA-ARS-WSU, United States

Dr. Natalia Marina Cardillo is a distinguished veterinary scientist from Argentina with a Ph.D. in Veterinary Sciences, specializing in parasitology and public health 🧫. Currently a Postdoctoral Research Associate at Washington State University 🇺🇸, she focuses on chemotherapeutic strategies for bovine babesiosis. With over two decades of academic and research excellence across UBA, CONICET, INTA, and USDA, she has led groundbreaking projects on zoonoses, antiparasitic drug resistance, and diagnostics. 🧬 Her contributions span teaching, diagnostics, and pharmaceutical clinical trials in veterinary medicine, earning her global recognition and prestigious fellowships.

Publication Profile

Google Scholar

Education

Dr. Natalia Marina Cardillo began her academic path with a Doctor of Veterinary Medicine degree (1997–2004) from the Universidad de Buenos Aires, Argentina, specializing in Public Health 🐕‍🦺🩺. She furthered her expertise by completing a Ph.D. in Veterinary Sciences with a focus on Parasitology and Public Health (2006–2012), earning the prestigious “summa cum laude” distinction for her thesis on Toxocara cati in murine models 🧬🧫. To complement her academic and research proficiency, she pursued a University Teaching Major in Veterinary and Biological Sciences (2014–2016), strengthening her role as an educator and mentor 📚👩‍🏫.

Experience

Dr. Natalia Marina Cardillo has led a distinguished career in parasitology, veterinary microbiology, and public health. Currently a Postdoctoral Research Associate at Washington State University 🐄💊, she focuses on developing novel treatments for bovine babesiosis. Previously, she served as Senior and Principal Scientist at CONICET-INTA 🇦🇷, leading studies on zoonotic parasitic diseases. With over two decades of academic roles at the Universidad de Buenos Aires 👩‍🏫🧫, she also contributed significantly to diagnostics, laboratory accreditation, and veterinary clinical trials. As founder of ALIANZA InVet 🧬🐕, she has pioneered ethical animal research and advanced pharmaceutical testing across Argentina.

Awards

Dr. Natalia Marina Cardillo has received numerous prestigious honors throughout her career. From 2023 to 2025, she was awarded a competitive Postdoctoral Fellowship by the USDA at Washington State University 🇺🇸🔬. In 2018, she won the NAVES entrepreneurship competition by Universidad Austral’s IAE Business School for her CRO-VET project 🏅💼. Her academic excellence was recognized early with a Ph.D. fellowship (2005–2010) in Public Health Veterinary Medicine and a Scientific Research Scholarship (2000–2002) in Parasitology at Universidad de Buenos Aires 🇦🇷📘—highlighting her dedication to veterinary science and innovation.

Research Focus

Dr. Natalia Marina Cardillo’s research is rooted in veterinary parasitology, with a strong emphasis on zoonotic diseases, public health, and epidemiology 🐛🧫🌍. Her work investigates parasites like Toxocara cati, Trichinella spp., and Aelurostrongylus abstrusus, exploring their life cycles, transmission, and pathology in animal hosts and their public health implications 💉📊. She also focuses on developing chemotherapeutic treatments for diseases such as bovine babesiosis, integrating pharmacology, immunology, and molecular diagnostics 🧬💊. Her interdisciplinary research contributes significantly to One Health, bridging human, animal, and environmental health.

Publication Top Notes

Prevalence of Toxocara cati and other parasites in cats’ faeces collected from the open spaces of public institutions: Buenos Aires, Argentina

Trichinella infection in wild animals from endemic regions of Argentina

Experimental Infection with Toxocara cati in BALB/c Mice, Migratory Behaviour and Pathological Changes

Prevalence of canine dirofilariosis in the city of Buenos Aires and its outskirts (Argentina)

Evaluation of the risk of transmission of Trichinella in pork production systems in Argentina

First report of Toxocara cati in the domestic land snail Rumina decollata

Soil contamination with eggs of Toxocara species in public parks of Karaj, Iran

Clinical, haematological, biochemical and economic impacts of Trichinella spiralis infection in pigs

First report of Aelurostrongylus abstrusus in domestic land snail Rumina decollata, in the Autonomous city of Buenos Aires

EXPERIMENTAL INFECTION WITH Toxocara cati IN PIGS: MIGRATORY PATTERN AND PATHOLOGICAL RESPONSE IN EARLY PHASE

Nuevos aportes al conocimiento de Trichinella y trichinellosis

Lior Zangi | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Lior Zangi | Drug Discovery and Development | Best Researcher Award

Prof. Lior Zangi, Icahn School of Medicine at Mount Sinai, United States

Prof. Lior Zangi is an Associate Professor of Cardiology and Genetics & Genomic Sciences at the Icahn School of Medicine at Mount Sinai, NY. He earned his Ph.D. in Immunology from the Weizmann Institute and completed postdoctoral training at Harvard Medical School. Renowned for his pioneering work in mRNA-based cardiovascular therapies, Prof. Zangi has received prestigious awards including the AHA Postdoctoral Fellowship and an endowed professorship in Cardiovascular Research. He is a founding board member of the Society for RNA Therapeutics and actively contributes to global scientific councils, manuscript reviews, and grant panels.

Publication Profile

Google Scholar

Education

Prof. Lior Zangi 🎓 began his academic journey with a B.Sc. in Biology from the Hebrew University, Givat-Ram, Jerusalem in 2000. He then earned his M.Sc. in Experimental and Developmental Medicine in 2003 from the Hebrew University Hadassah-Medical School under the guidance of Prof. Raphael Gorodetsky. In 2009, he completed his Ph.D. in Immunology at the Weizmann Institute of Science, mentored by Prof. Yair Reisner. 🌿 He continued his training as a postdoctoral fellow at Sheba Medical Center (2009–2010) under Prof. Benjamin Dekel and later at Harvard Medical School (2010–2014) with Professors Derrick Rossi and Kenneth Chien.

Awards

Prof. Lior Zangi 🌟 has earned numerous prestigious honors throughout his career. He received the ASH Travel Award in both 2008 and 2009 🧳, and in 2009, was granted a Postdoctoral Fellowship Award by the Israeli Budgeting Committee and Planning. In 2012, he was honored with both the ISSCR Travel Award and R&D Systems Travel Grant ✈️. His groundbreaking postdoctoral work earned him the AHA Fellowship Award in 2014 🫀. In 2017, he received the Mount Sinai Faculty Idea Prize 🧠, and in 2019, his research on mRNA therapy was recognized as highly influential 📜. In 2023, he was awarded the Endowed Chan Soon-Shiong Professorship in Cardiovascular Research 🏅.

Research Focus

Prof. Lior Zangi is a pioneering researcher in cardiovascular regenerative medicine, with a special focus on modified mRNA therapies, 🧬 stem cell biology, and 🫀 cardiac regeneration. His work centers on developing innovative strategies for repairing damaged heart tissue using modRNA, induced pluripotent stem cells (iPSCs), and heart-on-chip technologies. Zangi’s groundbreaking research has contributed to advancements in treating conditions like myocardial infarction and Barth syndrome, and has broad implications for tissue engineering, 💉 protein replacement therapy, and immune modulation. His contributions are reshaping modern precision medicine and offering new hope for heart failure patients worldwide.

Publication Top Notes

Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies

Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction

Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads

Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells

A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells

Isolation and characterization of nontubular sca-1+ lin− multipotent stem/progenitor cells from adult mouse kidney

Pkm2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration

mRNA-based protein replacement therapy for the heart

Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction